IE
CSTL icon

Israel Englander’s Castle Biosciences CSTL Stock Holding History

Israel Englander’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-460,000
Closed -$10M – 6153
2024
Q2 		$10M Buy
+460,000
New +$10.3M ﹤0.01% 2076
2022
Q4 		– Sell
-50,000
Closed -$1.3M – 6635
2022
Q3 		$1.3M Buy
+50,000
New +$1.4M ﹤0.01% 4115

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $112B AUM 36.28% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Israel Englander's CSTL Position: Q2 2026 in Review

Israel Englander reduced its Castle Biosciences (CSTL) stake by 42% in Q2 2026, selling an estimated $3.3M and leaving 205,369 shares worth $4.9M. The position accounts for ﹤0.01% of the portfolio, ranked #3014.

Israel Englander first reported a position in CSTL in Q3 2019 and has held it in 26 quarters since. The position peaked at $32.5M in Q4 2020. 175 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Israel Englander held 205,369 shares of Castle Biosciences worth $4.9M as of Q2 2026.
  • Israel Englander sold 147,950 Castle Biosciences shares in Q2 2026, an estimated $3.3M.
  • Castle Biosciences made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #3014 holding.
  • Israel Englander first reported a position in Castle Biosciences in Q3 2019 and has held it in 26 quarters since.
  • Israel Englander's Castle Biosciences position peaked at $32.5M in Q4 2020.
  • 175 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.